Production (Stage)
Cardiff Oncology, Inc.
CRDF
$3.86
$0.051.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -46.83% | -3.21% | 17.02% | 50.93% | 146.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -46.83% | -3.21% | 17.02% | 50.93% | 146.99% |
| Cost of Revenue | 30.83% | 25.11% | 20.17% | 18.37% | -11.53% |
| Gross Profit | -32.87% | -25.69% | -20.23% | -17.92% | 13.00% |
| SG&A Expenses | 28.24% | 10.50% | 6.36% | -25.16% | 1.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.10% | 21.31% | 16.47% | 3.18% | -8.22% |
| Operating Income | -31.55% | -21.68% | -16.46% | -2.76% | 9.28% |
| Income Before Tax | -34.19% | -26.24% | -21.83% | -5.63% | 10.80% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -34.19% | -26.24% | -21.83% | -5.63% | 10.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.19% | -26.24% | -21.83% | -5.63% | 10.80% |
| EBIT | -31.55% | -21.68% | -16.46% | -2.76% | 9.28% |
| EBITDA | -31.93% | -21.97% | -16.68% | -2.73% | 9.45% |
| EPS Basic | 9.90% | -4.02% | -16.15% | -5.29% | 10.78% |
| Normalized Basic EPS | 9.86% | -4.06% | -16.16% | -5.26% | 10.83% |
| EPS Diluted | 9.90% | -4.02% | -16.15% | -5.29% | 10.78% |
| Normalized Diluted EPS | 9.86% | -4.06% | -16.16% | -5.26% | 10.83% |
| Average Basic Shares Outstanding | 48.90% | 21.35% | 4.90% | 0.33% | 0.00% |
| Average Diluted Shares Outstanding | 48.90% | 21.35% | 4.90% | 0.33% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |